 Michael Arnold
Concepts (512)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rhabdomyosarcoma | 7 | 2023 | 56 | 2.110 |
Why?
| | Sarcoma | 6 | 2024 | 137 | 1.500 |
Why?
| | Cancer Survivors | 13 | 2023 | 205 | 1.480 |
Why?
| | Wilms Tumor | 4 | 2022 | 67 | 1.460 |
Why?
| | Desmoplastic Small Round Cell Tumor | 3 | 2022 | 3 | 1.430 |
Why?
| | Sarcoma, Ewing | 4 | 2022 | 65 | 1.420 |
Why?
| | Kidney Neoplasms | 5 | 2022 | 324 | 1.260 |
Why?
| | Neoplasms, Second Primary | 8 | 2023 | 92 | 1.220 |
Why?
| | Biomarkers, Tumor | 7 | 2023 | 1032 | 1.210 |
Why?
| | Bone Neoplasms | 4 | 2024 | 191 | 1.140 |
Why?
| | Immunohistochemistry | 6 | 2016 | 1624 | 1.010 |
Why?
| | Oncogene Proteins, Fusion | 7 | 2022 | 179 | 0.960 |
Why?
| | Thyroid Neoplasms | 5 | 2021 | 271 | 0.940 |
Why?
| | Rhabdomyosarcoma, Alveolar | 3 | 2021 | 10 | 0.840 |
Why?
| | Hirschsprung Disease | 5 | 2023 | 90 | 0.780 |
Why?
| | Gene Fusion | 3 | 2020 | 18 | 0.780 |
Why?
| | Gastritis | 3 | 2024 | 84 | 0.760 |
Why?
| | Myogenic Regulatory Factors | 8 | 2009 | 49 | 0.720 |
Why?
| | Child | 44 | 2024 | 18404 | 0.710 |
Why?
| | Gallbladder Diseases | 1 | 2019 | 6 | 0.650 |
Why?
| | Inclusion Bodies | 1 | 2019 | 24 | 0.640 |
Why?
| | Pyridines | 3 | 2022 | 419 | 0.640 |
Why?
| | Azabicyclo Compounds | 1 | 2017 | 5 | 0.590 |
Why?
| | Niacin | 1 | 2017 | 18 | 0.580 |
Why?
| | Neoplasms, Radiation-Induced | 5 | 2021 | 66 | 0.570 |
Why?
| | Sarcoma, Synovial | 2 | 2018 | 11 | 0.570 |
Why?
| | Helicobacter | 1 | 2016 | 5 | 0.550 |
Why?
| | Helicobacter Infections | 1 | 2016 | 25 | 0.540 |
Why?
| | Stomach | 1 | 2016 | 102 | 0.530 |
Why?
| | Breast Neoplasms | 6 | 2023 | 1846 | 0.530 |
Why?
| | Child, Preschool | 23 | 2024 | 9115 | 0.530 |
Why?
| | Carbodiimides | 2 | 2006 | 4 | 0.520 |
Why?
| | Imines | 2 | 2006 | 7 | 0.520 |
Why?
| | Alkaloids | 2 | 2006 | 22 | 0.520 |
Why?
| | Biopsy | 9 | 2019 | 1024 | 0.520 |
Why?
| | Infant | 19 | 2023 | 7944 | 0.520 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2017 | 92 | 0.510 |
Why?
| | Rhabdomyosarcoma, Embryonal | 3 | 2022 | 17 | 0.510 |
Why?
| | Chromosomal Proteins, Non-Histone | 2 | 2013 | 100 | 0.500 |
Why?
| | Neoplasms | 8 | 2022 | 2086 | 0.490 |
Why?
| | Adolescent | 30 | 2024 | 17802 | 0.490 |
Why?
| | Humans | 77 | 2024 | 114050 | 0.490 |
Why?
| | Anti-Bacterial Agents | 3 | 2022 | 1471 | 0.490 |
Why?
| | Frozen Sections | 1 | 2015 | 24 | 0.480 |
Why?
| | Colestipol | 1 | 2014 | 1 | 0.480 |
Why?
| | Ion Exchange Resins | 1 | 2014 | 5 | 0.480 |
Why?
| | Intestines | 2 | 2015 | 325 | 0.480 |
Why?
| | Thyroid Diseases | 1 | 2015 | 31 | 0.480 |
Why?
| | Allylamine | 1 | 2014 | 7 | 0.480 |
Why?
| | Pathology, Surgical | 1 | 2014 | 6 | 0.480 |
Why?
| | Transcription Factors | 6 | 2017 | 1526 | 0.480 |
Why?
| | Biopsy, Fine-Needle | 1 | 2015 | 65 | 0.470 |
Why?
| | Thyroid Gland | 1 | 2015 | 85 | 0.460 |
Why?
| | Practice Guidelines as Topic | 4 | 2019 | 1381 | 0.460 |
Why?
| | Gastrointestinal Agents | 1 | 2014 | 60 | 0.450 |
Why?
| | S100 Proteins | 1 | 2014 | 37 | 0.450 |
Why?
| | Specimen Handling | 1 | 2014 | 153 | 0.430 |
Why?
| | Cerebral Ventricle Neoplasms | 1 | 2013 | 4 | 0.430 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2013 | 15 | 0.420 |
Why?
| | Anticholesteremic Agents | 1 | 2014 | 129 | 0.420 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2014 | 224 | 0.410 |
Why?
| | DNA-Binding Proteins | 4 | 2013 | 1311 | 0.410 |
Why?
| | Female | 49 | 2024 | 59328 | 0.400 |
Why?
| | Rectum | 4 | 2023 | 151 | 0.400 |
Why?
| | Young Adult | 20 | 2023 | 10446 | 0.400 |
Why?
| | DNA | 2 | 2017 | 1350 | 0.370 |
Why?
| | Skin Neoplasms | 2 | 2019 | 754 | 0.370 |
Why?
| | Societies, Medical | 1 | 2014 | 655 | 0.360 |
Why?
| | Male | 40 | 2024 | 55400 | 0.350 |
Why?
| | Guideline Adherence | 1 | 2014 | 489 | 0.350 |
Why?
| | Soft Tissue Neoplasms | 2 | 2024 | 89 | 0.350 |
Why?
| | Guanidines | 2 | 2006 | 33 | 0.330 |
Why?
| | Predictive Value of Tests | 6 | 2017 | 1791 | 0.320 |
Why?
| | WT1 Proteins | 2 | 2022 | 12 | 0.320 |
Why?
| | Risk Assessment | 8 | 2021 | 2958 | 0.310 |
Why?
| | Adult | 27 | 2023 | 30377 | 0.310 |
Why?
| | Paired Box Transcription Factors | 3 | 2020 | 37 | 0.310 |
Why?
| | Retrospective Studies | 15 | 2024 | 12521 | 0.300 |
Why?
| | Risk Factors | 14 | 2023 | 8614 | 0.300 |
Why?
| | Gram-Negative Bacteria | 2 | 2018 | 66 | 0.290 |
Why?
| | Diagnosis, Differential | 5 | 2020 | 1331 | 0.290 |
Why?
| | Pediatrics | 1 | 2014 | 982 | 0.280 |
Why?
| | Bone Development | 1 | 2007 | 47 | 0.270 |
Why?
| | Colon | 3 | 2019 | 232 | 0.270 |
Why?
| | Pyrimidines | 2 | 2006 | 374 | 0.270 |
Why?
| | Intestinal Mucosa | 4 | 2019 | 532 | 0.260 |
Why?
| | Bone and Bones | 2 | 2018 | 277 | 0.260 |
Why?
| | Antineoplastic Agents | 4 | 2022 | 1875 | 0.250 |
Why?
| | Vinyl Compounds | 1 | 2005 | 5 | 0.250 |
Why?
| | Guanidine | 1 | 2005 | 18 | 0.250 |
Why?
| | Cartilage | 1 | 2007 | 182 | 0.250 |
Why?
| | Survivors | 2 | 2019 | 412 | 0.250 |
Why?
| | Genetic Predisposition to Disease | 4 | 2020 | 2090 | 0.240 |
Why?
| | Infant, Newborn | 10 | 2022 | 5038 | 0.240 |
Why?
| | Radiotherapy | 3 | 2021 | 175 | 0.240 |
Why?
| | Carcinoma, Renal Cell | 2 | 2020 | 168 | 0.240 |
Why?
| | Chondrocytes | 1 | 2007 | 198 | 0.240 |
Why?
| | Eosinophilia | 2 | 2024 | 186 | 0.230 |
Why?
| | Mutation | 5 | 2021 | 3338 | 0.230 |
Why?
| | Pathology | 1 | 2024 | 20 | 0.230 |
Why?
| | Duodenitis | 1 | 2024 | 7 | 0.220 |
Why?
| | Polyketides | 1 | 2023 | 3 | 0.220 |
Why?
| | Education, Distance | 1 | 2024 | 38 | 0.220 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2018 | 1356 | 0.220 |
Why?
| | Disease-Free Survival | 4 | 2020 | 618 | 0.210 |
Why?
| | Dysautonomia, Familial | 1 | 2023 | 2 | 0.210 |
Why?
| | Microbial Sensitivity Tests | 3 | 2022 | 300 | 0.210 |
Why?
| | Prognosis | 7 | 2023 | 3315 | 0.210 |
Why?
| | Orbital Neoplasms | 1 | 2023 | 19 | 0.210 |
Why?
| | SMARCB1 Protein | 2 | 2013 | 17 | 0.210 |
Why?
| | Eyelids | 1 | 2023 | 27 | 0.210 |
Why?
| | Mice | 17 | 2023 | 14845 | 0.210 |
Why?
| | Retinal Degeneration | 1 | 2023 | 30 | 0.210 |
Why?
| | Enterocolitis | 1 | 2023 | 33 | 0.200 |
Why?
| | Telomere Homeostasis | 2 | 2020 | 24 | 0.200 |
Why?
| | Bone Marrow | 1 | 2023 | 243 | 0.200 |
Why?
| | Ribonucleotide Reductases | 1 | 2022 | 21 | 0.200 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2019 | 695 | 0.200 |
Why?
| | Norwood Procedures | 1 | 2022 | 22 | 0.200 |
Why?
| | Age Factors | 4 | 2019 | 2886 | 0.200 |
Why?
| | Incidence | 7 | 2022 | 2314 | 0.190 |
Why?
| | Radiation Dosage | 2 | 2019 | 133 | 0.190 |
Why?
| | Muscle Proteins | 3 | 2017 | 210 | 0.190 |
Why?
| | Telomere Shortening | 1 | 2021 | 17 | 0.190 |
Why?
| | Vulvar Neoplasms | 1 | 2021 | 10 | 0.190 |
Why?
| | MEF2 Transcription Factors | 8 | 2009 | 55 | 0.190 |
Why?
| | Appendix | 1 | 2021 | 27 | 0.190 |
Why?
| | Radiation | 1 | 2021 | 24 | 0.190 |
Why?
| | Alphapapillomavirus | 1 | 2021 | 36 | 0.190 |
Why?
| | Neurodegenerative Diseases | 1 | 2023 | 92 | 0.190 |
Why?
| | Middle Aged | 15 | 2021 | 26607 | 0.190 |
Why?
| | Histone Deacetylases | 3 | 2007 | 194 | 0.190 |
Why?
| | MyoD Protein | 2 | 2021 | 28 | 0.180 |
Why?
| | Gonorrhea | 1 | 2022 | 54 | 0.180 |
Why?
| | Hypoplastic Left Heart Syndrome | 1 | 2022 | 114 | 0.180 |
Why?
| | Colonic Neoplasms | 2 | 2013 | 212 | 0.180 |
Why?
| | Biliary Tract Neoplasms | 1 | 2021 | 20 | 0.180 |
Why?
| | Kaplan-Meier Estimate | 3 | 2023 | 813 | 0.180 |
Why?
| | Drug Resistance, Bacterial | 1 | 2022 | 156 | 0.180 |
Why?
| | Forkhead Box Protein O1 | 1 | 2020 | 15 | 0.180 |
Why?
| | Schwann Cells | 1 | 2020 | 27 | 0.180 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2023 | 850 | 0.180 |
Why?
| | Colitis | 2 | 2021 | 223 | 0.180 |
Why?
| | Chromosome Breakpoints | 1 | 2020 | 6 | 0.170 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2018 | 159 | 0.170 |
Why?
| | Rhabdomyoma | 1 | 2020 | 9 | 0.170 |
Why?
| | Chromosomes, Human, Pair 19 | 1 | 2020 | 22 | 0.170 |
Why?
| | Nanoparticles | 2 | 2015 | 312 | 0.170 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2023 | 393 | 0.170 |
Why?
| | Phenotype | 5 | 2015 | 2784 | 0.170 |
Why?
| | Reproducibility of Results | 3 | 2021 | 2764 | 0.170 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2021 | 1880 | 0.170 |
Why?
| | Colitis, Ischemic | 1 | 2019 | 6 | 0.170 |
Why?
| | Diagnostic Errors | 3 | 2017 | 150 | 0.170 |
Why?
| | Ventricular Outflow Obstruction | 1 | 2020 | 38 | 0.170 |
Why?
| | Structure-Activity Relationship | 2 | 2018 | 499 | 0.170 |
Why?
| | Heart Neoplasms | 1 | 2020 | 49 | 0.170 |
Why?
| | Neurogenesis | 1 | 2020 | 102 | 0.170 |
Why?
| | Colitis, Ulcerative | 1 | 2021 | 104 | 0.170 |
Why?
| | Appendiceal Neoplasms | 1 | 2019 | 14 | 0.160 |
Why?
| | Neural Stem Cells | 1 | 2020 | 113 | 0.160 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2020 | 445 | 0.160 |
Why?
| | Carcinoid Tumor | 1 | 2019 | 23 | 0.160 |
Why?
| | Gallbladder | 1 | 2019 | 15 | 0.160 |
Why?
| | Prospective Studies | 5 | 2021 | 6195 | 0.160 |
Why?
| | Neurofibromatosis 1 | 1 | 2019 | 36 | 0.160 |
Why?
| | Vagina | 1 | 2021 | 146 | 0.160 |
Why?
| | Research Report | 1 | 2019 | 75 | 0.160 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2020 | 62 | 0.160 |
Why?
| | Receptor, Serotonin, 5-HT2A | 1 | 2019 | 19 | 0.160 |
Why?
| | Cholecystectomy | 1 | 2019 | 45 | 0.160 |
Why?
| | Telomere-Binding Proteins | 1 | 2020 | 88 | 0.160 |
Why?
| | Enteric Nervous System | 1 | 2019 | 26 | 0.160 |
Why?
| | Gene Rearrangement | 2 | 2022 | 135 | 0.160 |
Why?
| | Glucose Transporter Type 1 | 1 | 2018 | 43 | 0.150 |
Why?
| | Radiation Injuries | 1 | 2019 | 128 | 0.150 |
Why?
| | Anal Canal | 1 | 2019 | 83 | 0.150 |
Why?
| | Ohio | 2 | 2017 | 135 | 0.150 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2021 | 1145 | 0.150 |
Why?
| | Glioma | 1 | 2021 | 285 | 0.150 |
Why?
| | Digestive System Surgical Procedures | 1 | 2019 | 91 | 0.150 |
Why?
| | Age of Onset | 1 | 2019 | 444 | 0.150 |
Why?
| | Topoisomerase II Inhibitors | 1 | 2018 | 23 | 0.150 |
Why?
| | Curriculum | 1 | 2024 | 813 | 0.150 |
Why?
| | DNA Topoisomerases, Type II | 1 | 2018 | 44 | 0.150 |
Why?
| | Sequence Analysis, RNA | 1 | 2020 | 388 | 0.150 |
Why?
| | Epithelium | 1 | 2019 | 295 | 0.150 |
Why?
| | Escherichia coli | 2 | 2022 | 723 | 0.150 |
Why?
| | Carcinoma, Basal Cell | 1 | 2019 | 66 | 0.150 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2018 | 61 | 0.150 |
Why?
| | Eosinophilic Esophagitis | 1 | 2022 | 295 | 0.150 |
Why?
| | Animals | 17 | 2023 | 31567 | 0.150 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 152 | 0.140 |
Why?
| | Half-Life | 1 | 2017 | 141 | 0.140 |
Why?
| | Interleukin-8 | 1 | 2018 | 229 | 0.140 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2017 | 36 | 0.140 |
Why?
| | Povidone | 1 | 2017 | 5 | 0.140 |
Why?
| | Immunocompromised Host | 1 | 2019 | 192 | 0.140 |
Why?
| | Nephroma, Mesoblastic | 1 | 2017 | 3 | 0.140 |
Why?
| | Chemoradiotherapy | 2 | 2019 | 187 | 0.140 |
Why?
| | Cohort Studies | 6 | 2023 | 4883 | 0.140 |
Why?
| | Drug Discovery | 1 | 2018 | 123 | 0.140 |
Why?
| | Computer Communication Networks | 1 | 2017 | 32 | 0.140 |
Why?
| | Nuclear Receptor Coactivator 1 | 1 | 2017 | 10 | 0.140 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2021 | 284 | 0.140 |
Why?
| | Oncogene Protein p21(ras) | 1 | 2017 | 16 | 0.140 |
Why?
| | Excipients | 1 | 2017 | 49 | 0.140 |
Why?
| | Pathology, Clinical | 1 | 2017 | 32 | 0.140 |
Why?
| | Cellulose | 1 | 2017 | 57 | 0.140 |
Why?
| | Candidiasis | 1 | 2017 | 51 | 0.140 |
Why?
| | Esophagitis | 1 | 2017 | 65 | 0.130 |
Why?
| | Heart Transplantation | 1 | 2022 | 670 | 0.130 |
Why?
| | Liver Neoplasms | 1 | 2020 | 504 | 0.130 |
Why?
| | Survival Rate | 4 | 2023 | 1638 | 0.130 |
Why?
| | Oncolytic Viruses | 1 | 2015 | 5 | 0.130 |
Why?
| | Oncolytic Virotherapy | 1 | 2015 | 8 | 0.130 |
Why?
| | Enterocolitis, Neutropenic | 1 | 2015 | 6 | 0.130 |
Why?
| | Stereoisomerism | 2 | 2006 | 91 | 0.130 |
Why?
| | beta 2-Microglobulin | 1 | 2015 | 44 | 0.130 |
Why?
| | Virus Internalization | 1 | 2015 | 40 | 0.130 |
Why?
| | Cardiac Surgical Procedures | 1 | 2020 | 414 | 0.130 |
Why?
| | Clinical Trials as Topic | 2 | 2020 | 926 | 0.130 |
Why?
| | Immunotherapy | 2 | 2018 | 473 | 0.130 |
Why?
| | Receptors, Virus | 1 | 2015 | 75 | 0.120 |
Why?
| | Sarcoma, Experimental | 1 | 2015 | 5 | 0.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2019 | 660 | 0.120 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 924 | 0.120 |
Why?
| | Information Dissemination | 1 | 2017 | 185 | 0.120 |
Why?
| | Granuloma, Plasma Cell | 1 | 2015 | 12 | 0.120 |
Why?
| | Granuloma, Foreign-Body | 1 | 2015 | 10 | 0.120 |
Why?
| | Colesevelam Hydrochloride | 1 | 2014 | 7 | 0.120 |
Why?
| | Cholestyramine Resin | 1 | 2014 | 7 | 0.120 |
Why?
| | Gastrointestinal Tract | 1 | 2017 | 169 | 0.120 |
Why?
| | Herpesvirus 1, Human | 1 | 2015 | 76 | 0.120 |
Why?
| | Neuroblastoma | 1 | 2015 | 133 | 0.120 |
Why?
| | Thyroidectomy | 1 | 2015 | 62 | 0.120 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2016 | 308 | 0.120 |
Why?
| | Desmin | 1 | 2014 | 31 | 0.120 |
Why?
| | Albumins | 1 | 2015 | 89 | 0.120 |
Why?
| | Interleukin-6 | 1 | 2018 | 673 | 0.120 |
Why?
| | Social Media | 1 | 2017 | 131 | 0.120 |
Why?
| | Muscle, Skeletal | 4 | 2007 | 1468 | 0.120 |
Why?
| | Quality Control | 1 | 2014 | 143 | 0.120 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2015 | 170 | 0.120 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2015 | 59 | 0.110 |
Why?
| | Cerebral Ventricles | 1 | 2014 | 47 | 0.110 |
Why?
| | Tubulin | 1 | 2015 | 122 | 0.110 |
Why?
| | Paclitaxel | 1 | 2015 | 190 | 0.110 |
Why?
| | Keratins | 1 | 2014 | 176 | 0.110 |
Why?
| | MicroRNAs | 1 | 2020 | 600 | 0.110 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 544 | 0.110 |
Why?
| | Treatment Outcome | 5 | 2022 | 9049 | 0.110 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2014 | 60 | 0.110 |
Why?
| | Microscopy | 1 | 2014 | 125 | 0.110 |
Why?
| | Vascular Malformations | 1 | 2014 | 48 | 0.110 |
Why?
| | Cerebral Hemorrhage | 1 | 2014 | 96 | 0.110 |
Why?
| | Ganglioneuroma | 1 | 2013 | 2 | 0.110 |
Why?
| | Ileal Neoplasms | 1 | 2013 | 3 | 0.110 |
Why?
| | Follow-Up Studies | 5 | 2019 | 4392 | 0.110 |
Why?
| | Glucose-6-Phosphatase | 1 | 2013 | 31 | 0.110 |
Why?
| | Food | 1 | 2015 | 160 | 0.110 |
Why?
| | Repressor Proteins | 2 | 2006 | 367 | 0.110 |
Why?
| | Hypertrophy | 2 | 2018 | 110 | 0.110 |
Why?
| | United States | 7 | 2019 | 12137 | 0.110 |
Why?
| | Cell Line, Tumor | 5 | 2019 | 2700 | 0.110 |
Why?
| | Lateral Ventricles | 1 | 2013 | 24 | 0.110 |
Why?
| | Calcium Phosphates | 1 | 2013 | 24 | 0.100 |
Why?
| | Human Growth Hormone | 1 | 2013 | 38 | 0.100 |
Why?
| | Gastrointestinal Diseases | 1 | 2015 | 182 | 0.100 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2013 | 134 | 0.100 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2013 | 52 | 0.100 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2013 | 46 | 0.100 |
Why?
| | Neutropenia | 1 | 2013 | 123 | 0.100 |
Why?
| | COS Cells | 3 | 2007 | 175 | 0.100 |
Why?
| | Sepsis | 1 | 2018 | 507 | 0.100 |
Why?
| | Proportional Hazards Models | 3 | 2020 | 1078 | 0.100 |
Why?
| | Endocytosis | 1 | 2013 | 146 | 0.100 |
Why?
| | Patient Selection | 1 | 2015 | 629 | 0.100 |
Why?
| | Enteritis | 2 | 2024 | 82 | 0.100 |
Why?
| | Brain Neoplasms | 1 | 2019 | 966 | 0.100 |
Why?
| | Colonic Polyps | 1 | 2013 | 67 | 0.100 |
Why?
| | Rhabdoid Tumor | 1 | 2012 | 80 | 0.100 |
Why?
| | Feasibility Studies | 1 | 2014 | 735 | 0.100 |
Why?
| | Spinal Cord | 1 | 2014 | 344 | 0.100 |
Why?
| | Neurosurgical Procedures | 1 | 2013 | 150 | 0.100 |
Why?
| | Adenoma | 1 | 2013 | 187 | 0.090 |
Why?
| | Recurrence | 3 | 2024 | 925 | 0.090 |
Why?
| | Colonoscopy | 1 | 2013 | 197 | 0.090 |
Why?
| | RNA, Small Interfering | 1 | 2013 | 534 | 0.090 |
Why?
| | Constipation | 2 | 2023 | 75 | 0.090 |
Why?
| | Sarcomeres | 2 | 2007 | 90 | 0.090 |
Why?
| | Combined Modality Therapy | 1 | 2013 | 1117 | 0.090 |
Why?
| | Longitudinal Studies | 3 | 2021 | 2384 | 0.080 |
Why?
| | Aged | 6 | 2019 | 18971 | 0.080 |
Why?
| | SEER Program | 2 | 2021 | 195 | 0.080 |
Why?
| | Leukemia, Myelomonocytic, Acute | 1 | 2009 | 7 | 0.080 |
Why?
| | Muscle Fibers, Skeletal | 2 | 2007 | 185 | 0.080 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2009 | 62 | 0.080 |
Why?
| | Coccidioidomycosis | 1 | 2008 | 7 | 0.080 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 1690 | 0.080 |
Why?
| | Cell Proliferation | 3 | 2018 | 2173 | 0.080 |
Why?
| | Polyethylene Glycols | 1 | 2013 | 561 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2008 | 47 | 0.070 |
Why?
| | Risk | 2 | 2021 | 810 | 0.070 |
Why?
| | Doxorubicin | 2 | 2023 | 286 | 0.070 |
Why?
| | Waste Disposal, Fluid | 1 | 2008 | 45 | 0.070 |
Why?
| | Gene Expression Regulation, Developmental | 3 | 2007 | 801 | 0.070 |
Why?
| | Case-Control Studies | 3 | 2021 | 3003 | 0.070 |
Why?
| | Canada | 2 | 2019 | 320 | 0.070 |
Why?
| | Mice, Transgenic | 3 | 2007 | 1947 | 0.070 |
Why?
| | Dwarfism | 1 | 2007 | 15 | 0.070 |
Why?
| | Pressure | 1 | 2008 | 214 | 0.070 |
Why?
| | Myeloid Cells | 1 | 2008 | 126 | 0.070 |
Why?
| | Gastroschisis | 1 | 2006 | 15 | 0.070 |
Why?
| | Colectomy | 2 | 2019 | 86 | 0.070 |
Why?
| | Tumor Microenvironment | 2 | 2019 | 428 | 0.070 |
Why?
| | Actinin | 1 | 2006 | 13 | 0.060 |
Why?
| | Lung Neoplasms | 1 | 2018 | 2159 | 0.060 |
Why?
| | Cell Differentiation | 3 | 2008 | 1696 | 0.060 |
Why?
| | Neoplastic Stem Cells | 1 | 2009 | 327 | 0.060 |
Why?
| | Myopathies, Structural, Congenital | 1 | 2005 | 6 | 0.060 |
Why?
| | Neovascularization, Physiologic | 1 | 2007 | 174 | 0.060 |
Why?
| | Alkylation | 1 | 2005 | 18 | 0.060 |
Why?
| | Promoter Regions, Genetic | 2 | 2006 | 1131 | 0.060 |
Why?
| | Aged, 80 and over | 4 | 2017 | 6307 | 0.060 |
Why?
| | Neoplasm Staging | 2 | 2020 | 1162 | 0.060 |
Why?
| | Osteogenesis | 1 | 2007 | 181 | 0.060 |
Why?
| | Molecular Sequence Data | 5 | 2007 | 2783 | 0.060 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2015 | 742 | 0.060 |
Why?
| | Base Sequence | 4 | 2013 | 2114 | 0.060 |
Why?
| | Time Factors | 3 | 2019 | 6077 | 0.060 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2006 | 236 | 0.060 |
Why?
| | Molecular Medicine | 1 | 2024 | 2 | 0.060 |
Why?
| | Daunorubicin | 1 | 2023 | 24 | 0.060 |
Why?
| | Podophyllotoxin | 1 | 2023 | 7 | 0.050 |
Why?
| | Anthracyclines | 1 | 2023 | 42 | 0.050 |
Why?
| | Public Opinion | 1 | 2024 | 59 | 0.050 |
Why?
| | Kinetin | 1 | 2023 | 1 | 0.050 |
Why?
| | Gait Ataxia | 1 | 2023 | 5 | 0.050 |
Why?
| | T-Lymphocytes | 2 | 2021 | 1735 | 0.050 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2015 | 314 | 0.050 |
Why?
| | Breast | 1 | 2023 | 138 | 0.050 |
Why?
| | Necrosis | 1 | 2023 | 209 | 0.050 |
Why?
| | Placenta | 1 | 2008 | 628 | 0.050 |
Why?
| | Educational Measurement | 1 | 2024 | 235 | 0.050 |
Why?
| | Deoxyadenine Nucleotides | 1 | 2022 | 13 | 0.050 |
Why?
| | Neisseria gonorrhoeae | 1 | 2022 | 20 | 0.050 |
Why?
| | Allosteric Regulation | 1 | 2022 | 81 | 0.050 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2024 | 201 | 0.050 |
Why?
| | Carrier Proteins | 1 | 2006 | 694 | 0.050 |
Why?
| | Mice, SCID | 2 | 2015 | 312 | 0.050 |
Why?
| | Gene Ontology | 1 | 2021 | 46 | 0.050 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2023 | 224 | 0.050 |
Why?
| | Haploinsufficiency | 1 | 2021 | 42 | 0.050 |
Why?
| | Colon, Sigmoid | 1 | 2021 | 15 | 0.050 |
Why?
| | Papillomaviridae | 1 | 2021 | 101 | 0.050 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2021 | 181 | 0.050 |
Why?
| | CTLA-4 Antigen | 1 | 2021 | 76 | 0.050 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2021 | 44 | 0.050 |
Why?
| | Neoplasm Grading | 1 | 2021 | 241 | 0.040 |
Why?
| | Myocardium | 1 | 2006 | 911 | 0.040 |
Why?
| | Administration, Oral | 1 | 2023 | 725 | 0.040 |
Why?
| | DNA Copy Number Variations | 1 | 2021 | 153 | 0.040 |
Why?
| | Gene Expression Regulation | 2 | 2007 | 2322 | 0.040 |
Why?
| | Cloaca | 1 | 2021 | 47 | 0.040 |
Why?
| | Neoplasm, Residual | 1 | 2021 | 104 | 0.040 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2021 | 182 | 0.040 |
Why?
| | Mice, Knockout | 4 | 2007 | 2563 | 0.040 |
Why?
| | Students, Medical | 1 | 2024 | 262 | 0.040 |
Why?
| | Constriction, Pathologic | 1 | 2021 | 207 | 0.040 |
Why?
| | Transcription Initiation Site | 1 | 2020 | 40 | 0.040 |
Why?
| | Genomic Instability | 1 | 2020 | 38 | 0.040 |
Why?
| | Genes, ras | 1 | 2020 | 91 | 0.040 |
Why?
| | Eosinophils | 1 | 2022 | 276 | 0.040 |
Why?
| | Homeodomain Proteins | 1 | 2023 | 465 | 0.040 |
Why?
| | Tissue Donors | 1 | 2022 | 314 | 0.040 |
Why?
| | Internet | 1 | 2024 | 591 | 0.040 |
Why?
| | Hepatocyte Growth Factor | 1 | 2019 | 32 | 0.040 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2019 | 127 | 0.040 |
Why?
| | Aneuploidy | 1 | 2020 | 84 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2019 | 243 | 0.040 |
Why?
| | Tumor Burden | 1 | 2020 | 258 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2019 | 67 | 0.040 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2019 | 56 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2022 | 1144 | 0.040 |
Why?
| | Introns | 1 | 2020 | 227 | 0.040 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2013 | 307 | 0.040 |
Why?
| | Anorectal Malformations | 1 | 2020 | 102 | 0.040 |
Why?
| | North America | 1 | 2019 | 255 | 0.040 |
Why?
| | Receptors, Interleukin-8A | 1 | 2018 | 5 | 0.040 |
Why?
| | Cytokine Receptor gp130 | 1 | 2018 | 10 | 0.040 |
Why?
| | Diarrhea | 1 | 2019 | 170 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2019 | 217 | 0.040 |
Why?
| | Abdominal Pain | 1 | 2019 | 134 | 0.040 |
Why?
| | Gene Frequency | 1 | 2020 | 476 | 0.040 |
Why?
| | Hydrazines | 1 | 2018 | 27 | 0.040 |
Why?
| | Linkage Disequilibrium | 1 | 2019 | 245 | 0.040 |
Why?
| | Appendicitis | 1 | 2019 | 112 | 0.040 |
Why?
| | Quinoxalines | 1 | 2018 | 60 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2018 | 148 | 0.040 |
Why?
| | Osteosarcoma | 1 | 2018 | 65 | 0.040 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2018 | 154 | 0.040 |
Why?
| | Immunotherapy, Adoptive | 1 | 2019 | 184 | 0.040 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 111 | 0.040 |
Why?
| | Genetic Loci | 1 | 2019 | 262 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2018 | 274 | 0.040 |
Why?
| | DNA Methylation | 1 | 2021 | 493 | 0.040 |
Why?
| | Computer Simulation | 1 | 2021 | 873 | 0.040 |
Why?
| | Mice, Mutant Strains | 2 | 2008 | 271 | 0.040 |
Why?
| | Leukocytes | 1 | 2018 | 272 | 0.040 |
Why?
| | Up-Regulation | 1 | 2020 | 802 | 0.030 |
Why?
| | Disease Management | 1 | 2021 | 556 | 0.030 |
Why?
| | HLA Antigens | 1 | 2018 | 220 | 0.030 |
Why?
| | Ventricular Function, Left | 1 | 2020 | 477 | 0.030 |
Why?
| | Molecular Structure | 1 | 2018 | 434 | 0.030 |
Why?
| | Recovery of Function | 1 | 2020 | 573 | 0.030 |
Why?
| | Staining and Labeling | 1 | 2017 | 134 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 723 | 0.030 |
Why?
| | Medical Informatics | 1 | 2017 | 89 | 0.030 |
Why?
| | Biomarkers | 2 | 2022 | 3397 | 0.030 |
Why?
| | Embryo, Mammalian | 2 | 2007 | 213 | 0.030 |
Why?
| | Palliative Care | 1 | 2022 | 641 | 0.030 |
Why?
| | Models, Statistical | 1 | 2019 | 595 | 0.030 |
Why?
| | Tissue Array Analysis | 1 | 2015 | 48 | 0.030 |
Why?
| | Nephrectomy | 1 | 2017 | 149 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 2 | 2015 | 2272 | 0.030 |
Why?
| | Osteonectin | 1 | 2015 | 2 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 1837 | 0.030 |
Why?
| | Protein Conformation | 1 | 2018 | 803 | 0.030 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2007 | 270 | 0.030 |
Why?
| | Signal Transduction | 3 | 2019 | 4501 | 0.030 |
Why?
| | Caveolin 1 | 1 | 2015 | 20 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 521 | 0.030 |
Why?
| | Sulfonamides | 1 | 2018 | 444 | 0.030 |
Why?
| | Genetic Variation | 1 | 2020 | 868 | 0.030 |
Why?
| | Immunoenzyme Techniques | 1 | 2015 | 192 | 0.030 |
Why?
| | Skin | 1 | 2019 | 653 | 0.030 |
Why?
| | Tissue Distribution | 1 | 2015 | 285 | 0.030 |
Why?
| | Cerebral Infarction | 1 | 2014 | 39 | 0.030 |
Why?
| | Mice, Nude | 1 | 2015 | 628 | 0.030 |
Why?
| | Thoracic Vertebrae | 1 | 2014 | 68 | 0.030 |
Why?
| | Dwarfism, Pituitary | 1 | 2013 | 3 | 0.030 |
Why?
| | Multiple Endocrine Neoplasia Type 2b | 1 | 2013 | 6 | 0.030 |
Why?
| | Fatal Outcome | 1 | 2014 | 281 | 0.030 |
Why?
| | Models, Molecular | 1 | 2018 | 1368 | 0.030 |
Why?
| | Disease Progression | 1 | 2020 | 2371 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2015 | 845 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2019 | 1176 | 0.030 |
Why?
| | Anastomosis, Surgical | 1 | 2013 | 135 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2022 | 3498 | 0.030 |
Why?
| | Hyperplasia | 1 | 2013 | 163 | 0.030 |
Why?
| | Microscopy, Electron | 1 | 2013 | 408 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2013 | 3861 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2023 | 2122 | 0.020 |
Why?
| | Lumbar Vertebrae | 1 | 2014 | 207 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2015 | 1075 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2013 | 373 | 0.020 |
Why?
| | Amino Acid Sequence | 2 | 2006 | 1981 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2013 | 304 | 0.020 |
Why?
| | DNA Primers | 1 | 2013 | 508 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2464 | 0.020 |
Why?
| | Cell Line | 2 | 2007 | 2629 | 0.020 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2015 | 636 | 0.020 |
Why?
| | Protein Binding | 2 | 2007 | 1888 | 0.020 |
Why?
| | Gene Expression Profiling | 2 | 2009 | 1518 | 0.020 |
Why?
| | Heart Arrest | 1 | 2014 | 293 | 0.020 |
Why?
| | Reactive Oxygen Species | 1 | 2013 | 522 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2021 | 4595 | 0.020 |
Why?
| | Leukemia Virus, Murine | 1 | 2009 | 16 | 0.020 |
Why?
| | Colony-Forming Units Assay | 1 | 2009 | 88 | 0.020 |
Why?
| | Interferon Regulatory Factors | 1 | 2009 | 31 | 0.020 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2009 | 48 | 0.020 |
Why?
| | Transduction, Genetic | 1 | 2009 | 113 | 0.020 |
Why?
| | Mice, Inbred C57BL | 2 | 2009 | 4681 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2009 | 237 | 0.020 |
Why?
| | Granulocytes | 1 | 2008 | 75 | 0.020 |
Why?
| | Water Movements | 1 | 2008 | 22 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2009 | 438 | 0.020 |
Why?
| | Sewage | 1 | 2008 | 27 | 0.020 |
Why?
| | Leupeptins | 1 | 2007 | 9 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2015 | 2550 | 0.020 |
Why?
| | Connectin | 1 | 2007 | 30 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2009 | 552 | 0.020 |
Why?
| | Ubiquitin | 1 | 2007 | 57 | 0.020 |
Why?
| | Morbidity | 1 | 2008 | 277 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2007 | 133 | 0.020 |
Why?
| | Hematopoiesis | 1 | 2008 | 170 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2008 | 266 | 0.020 |
Why?
| | Isoenzymes | 1 | 2007 | 283 | 0.020 |
Why?
| | Mice, Inbred ICR | 1 | 2006 | 108 | 0.020 |
Why?
| | Feedback, Physiological | 1 | 2006 | 68 | 0.020 |
Why?
| | Protein Methyltransferases | 1 | 2006 | 2 | 0.020 |
Why?
| | Neoplasm Proteins | 1 | 2009 | 385 | 0.020 |
Why?
| | Lung | 1 | 2018 | 3521 | 0.020 |
Why?
| | Gene Deletion | 1 | 2007 | 356 | 0.020 |
Why?
| | Veins | 1 | 2006 | 55 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2007 | 777 | 0.020 |
Why?
| | Monocytes | 1 | 2008 | 503 | 0.020 |
Why?
| | Cell Movement | 1 | 2009 | 863 | 0.020 |
Why?
| | Down-Regulation | 1 | 2007 | 594 | 0.020 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2006 | 96 | 0.010 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2006 | 225 | 0.010 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2008 | 285 | 0.010 |
Why?
| | Enhancer Elements, Genetic | 1 | 2005 | 151 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 2007 | 917 | 0.010 |
Why?
| | Arteries | 1 | 2006 | 246 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2006 | 796 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3039 | 0.010 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2006 | 388 | 0.010 |
Why?
| | Gene Expression | 1 | 2006 | 1417 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2005 | 1310 | 0.010 |
Why?
| | Pregnancy | 1 | 2008 | 5499 | 0.010 |
Why?
|
|
Arnold's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|